TCGA-BT-A20P-01A-11R-A14Y-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 17.87122208
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.190
- HYPOXIA+0.180
- HEDGEHOG_SIGNALING+0.170
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.140
- CHOLESTEROL_HOMEOSTASIS+0.100
- UV_RESPONSE_UP+0.080
- WNT_BETA_CATENIN_SIGNALING+0.080
- XENOBIOTIC_METABOLISM+0.080
- OXIDATIVE_PHOSPHORYLATION+0.060
- BILE_ACID_METABOLISM+0.030
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- PROTEIN_SECRETION-0.320
- MYC_TARGETS_V1-0.300
- E2F_TARGETS-0.280
- UV_RESPONSE_DN-0.280
- G2M_CHECKPOINT-0.270
- MITOTIC_SPINDLE-0.270
- INTERFERON_GAMMA_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D6-A4ZB-01A-11R-A24Z-07 | — | — | 0.800 |
| 2 | SRR33532762 | — | C | 0.773 |
| 3 | TCGA-E7-A7DU-01A-11R-A32O-07 | — | — | 0.750 |
| 4 | TCGA-2F-A9KR-01A-11R-A38B-07 | — | — | 0.748 |
| 5 | R71 | — | — | 0.742 |
| 6 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.739 |
| 7 | AUR-AER6-TTM2-A-1-1-R-A742-41 | — | C | 0.737 |
| 8 | TCGA-NJ-A7XG-01A-12R-A39D-07 | — | cohortA1 | 0.733 |
| 9 | SRR1446092 | GTEX | — | 0.728 |
| 10 | MDT-AP-0819 | Med | Medulloblastoma | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |